经导管主动脉瓣植入术后阿司匹林联合或不联合氯吡格雷
该随机对照试验纳入无长期抗凝指征的TAVI患者,按1:1分配至单用阿司匹林组331例或阿司匹林联合氯吡格雷3个月组334例。主要终点为12个月内所有出血和非手术相关出血,联合组均显著高于单用组(风险比分别为0.57和0.61)。次要复合终点1(心血管死亡、非手术相关出血、卒中或心肌梗死)单用组23.0%对联合组31.1%,单用组不劣于且优于联合组。作者结论认为无口服抗凝指征的TAVI患者,单用阿司匹林较联合氯吡格雷3个月可减少出血及出血或血栓栓塞复合事件。
要点
- 无长期抗凝指征的TAVI患者,单用阿司匹林组12个月内所有出血15.1%,联合氯吡格雷3个月组26.6%(风险比0.57;95%CI 0.42-0.77;P=0.001)。
- 非手术相关出血单用阿司匹林组15.1%对联合组24.9%(风险比0.61;95%CI 0.44-0.83;P=0.005)。
- 次要复合终点1(心血管死亡、非手术相关出血、卒中或心肌梗死)单用组23.0%对联合组31.1%(差异-8.2个百分点;非劣效95%CI -14.9至-1.5;P<0.001;优效性风险比0.74;95%CI 0.57-0.95;P=0.04)。
- 次要复合终点2(心血管死亡、缺血性卒中或心肌梗死)单用组9.7%对联合组9.9%(差异-0.2个百分点;非劣效95%CI -4.7至4.3;P=0.004;优效性风险比0.98;95%CI 0.62-1.55;P=0.93)。
- 试验期间单用阿司匹林组44例(13.3%)和联合组32例(9.6%)接受口服抗凝治疗。
适用人群与场景
- 接受经导管主动脉瓣植入术(TAVI)且无长期抗凝指征的患者。
处置流程与药物剂量
- 单用阿司匹林组:阿司匹林单药治疗。
- 联合组:阿司匹林联合氯吡格雷治疗3个月。
研究设计与关键结果
- 随机对照试验,纳入无长期抗凝指征的TAVI患者,单用阿司匹林组331例,阿司匹林联合氯吡格雷3个月组334例。
- 主要终点:所有出血单用阿司匹林组50例(15.1%)对联合组89例(26.6%),风险比0.57(95%CI 0.42-0.77;P=0.001)。
- 主要终点:非手术相关出血单用阿司匹林组50例(15.1%)对联合组83例(24.9%),风险比0.61(95%CI 0.44-0.83;P=0.005)。
- 次要复合终点1:单用阿司匹林组76例(23.0%)对联合组104例(31.1%),差异-8.2个百分点(非劣效95%CI -14.9至-1.5;P<0.001;优效性风险比0.74;95%CI 0.57-0.95;P=0.04)。
- 次要复合终点2:单用阿司匹林组32例(9.7%)对联合组33例(9.9%),差异-0.2个百分点(非劣效95%CI -4.7至4.3;P=0.004;优效性风险比0.98;95%CI 0.62-1.55;P=0.93)。
- 试验期间接受口服抗凝治疗:单用阿司匹林组44例(13.3%),联合组32例(9.6%)。
证据类型、等级与局限
- 随机对照试验。
- 由荷兰健康研究与发展组织资助。
- EU Clinical Trials Register号2013-003125-28;ClinicalTrials.gov号NCT02247128。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于接受TAVI且无口服抗凝指征的患者,单用阿司匹林较阿司匹林联合氯吡格雷3个月可减少出血及出血或血栓栓塞复合事件。
- 适用人群为无长期抗凝指征的TAVI患者;有长期抗凝指征者不适用。
- 作者结论认为,在无口服抗凝指征的TAVI患者中,阿司匹林单药治疗1年出血及出血或血栓栓塞复合事件的发生率显著低于阿司匹林联合氯吡格雷3个月。
指南或共识出处
- POPular TAVI试验(EU Clinical Trials Register号2013-003125-28;ClinicalTrials.gov号NCT02247128)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The effect of single as compared with dual antiplatelet treatment on bleeding and thromboembolic events after transcatheter aortic-valve implantation (TAVI) in patients who do not have an indication for long-term anticoagulation has not been well studied.
METHODS: In a randomized, controlled trial, we assigned a subgroup of patients who were undergoing TAVI and did not have an indication for long-term anticoagulation, in a 1:1 ratio, to receive aspirin alone or aspirin plus clopidogrel for 3 months. The two primary outcomes were all bleeding (including minor, major, and life-threatening or disabling bleeding) and non-procedure-related bleeding over a period of 12 months. Most bleeding at the TAVI puncture site was counted as non-procedure-related. The two secondary outcomes were a composite of death from cardiovascular causes, non-procedure-related bleeding, stroke, or myocardial infarction (secondary composite 1) and a composite of death from cardiovascular causes, ischemic stroke, or myocardial infarction (secondary composite 2) at 1 year, with both outcomes tested sequentially for noninferiority (noninferiority margin, 7.5 percentage points) and superiority.
RESULTS: A total of 331 patients were assigned to receive aspirin alone and 334 were assigned to receive aspirin plus clopidogrel. A bleeding event occurred in 50 patients (15.1%) receiving aspirin alone and in 89 (26.6%) receiving aspirin plus clopidogrel (risk ratio, 0.57; 95% confidence interval [CI], 0.42 to 0.77; P = 0.001). Non-procedure-related bleeding occurred in 50 patients (15.1%) and 83 patients (24.9%), respectively (risk ratio, 0.61; 95% CI, 0.44 to 0.83; P = 0.005). A secondary composite 1 event occurred in 76 patients (23.0%) receiving aspirin alone and in 104 (31.1%) receiving aspirin plus clopidogrel (difference, -8.2 percentage points; 95% CI for noninferiority, -14.9 to -1.5; P<0.001; risk ratio, 0.74; 95% CI for superiority, 0.57 to 0.95; P = 0.04). A secondary composite 2 event occurred in 32 patients (9.7%) and 33 patients (9.9%), respectively (difference, -0.2 percentage points; 95% CI for noninferiority, -4.7 to 4.3; P = 0.004; risk ratio, 0.98; 95% CI for superiority, 0.62 to 1.55; P = 0.93). A total of 44 patients (13.3%) and 32 (9.6%), respectively, received oral anticoagulation during the trial.
CONCLUSIONS: Among patients undergoing TAVI who did not have an indication for oral anticoagulation, the incidence of bleeding and the composite of bleeding or thromboembolic events at 1 year were significantly less frequent with aspirin than with aspirin plus clopidogrel administered for 3 months. (Funded by the Netherlands Organization for Health Research and Development; POPular TAVI EU Clinical Trials Register number, 2013-003125-28; ClinicalTrials.gov number, NCT02247128.).
参考来源
- Brouwer J, Nijenhuis VJ, Delewi R, et al. Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation. N Engl J Med. 2020. PMID: 32865376. doi:10.1056/NEJMoa2017815
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。